GI Dynamics has released positive interim data from a two-year trial designed to evaluate the company’s EndoBarrier therapy (EBT) in conjunction with liraglutide — a non-insulin medicine- for the treatment for type 2 diabetes.
The one-year interim data show the endoscopically delivered device and liraglutide generated “significantly better” reduction in hemoglobin A1c levels and weight versus EBT alone or liraglutide alone. Further, the combo resulted in a 2.1 percent absolute reduction in HbA1c, which is 95 percent attainment of the overall target.
The data was presented at the Endocrine Society’s ENDO 2016 meeting in Boston, Mass. — Anisa Jibrell